• Mashup Score: 1

    ESC 23 – We are joined onsite by Dr Mathieu Kerneis (Pitie Salpetriere APHP University Hospital, FR) and Dr Gilles Montalescot to discuss the findings from the ARAMIS trial. ARAMIS was the

    Tweet Tweets with this article
    • 🫀NEW #ESCCongress #LBCT Interview 💫Dr @mathieukerneis and Dr Gilles Montalescot discuss findings from the #ARAMIS trial. 📽️👉 https://t.co/zg9bByyrEO 📊Results showed that #anakinra was safe but did not reduce the complications of acute myocarditis. #ESC2023 #CardioTwitter https://t.co/9AGMF59hbX

  • Mashup Score: 0

    About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…

    Tweet Tweets with this article
    • I'm honoured to have been asked to write this editorial for @EUplatinum about non-metastatic #ProstateCancer and the just-published subgroup analysis of the #ARAMIS darolutamide trial. https://t.co/l8Tp7wumZG

  • Mashup Score: 0

    Alicia Morgans is joined by Christian Gratzke to discuss data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting around the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. The ARAMIS trial was a phase three multicenter randomized control trial, comparing darolutamide versus placebo in combination with ADT in non-metastatic…

    Tweet Tweets with this article
    • Time course profile of adverse events with darolutamide in the #ARAMIS trial. @cgratzke @UniFreiburg joins @CaPsurvivorship @DanaFarber to discuss data presented at #ESMO21. #WatchNow on UroToday > https://t.co/qOch41F3ez https://t.co/equEa1xs4x